Azabenzoxazoles for the treatment of cns disorders

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 519/00 (2006.01) A61K 31/551 (2006.01) A61P 25/18 (2006.01)

Patent

CA 2587826

The present invention relates to .alpha.7 nicotinic receptor agonists of formula I as described herein and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal an .alpha.7 nicotinic receptor agonist of formula I as shown herein. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant .alpha.7 nicotinic receptor agonist of formula I.

Cette invention concerne des agonistes du récepteur a7-nicotinique représentés par la formule (I), tels que décrits dans les pièces descriptives de la demande, ainsi qu'un procédé pour traiter les troubles du système nerveux central et d'autres troubles chez un mammifère, notamment l'homme, en administrant à ce mammifère un agoniste du récepteur a7-nicotinique de formule (I). Cette invention concerne également des compositions pharmaceutiques contenant un véhicule pharmaceutiquement acceptable et un agoniste du récepteur a7-nicotinique de formule (I), pénétrant dans le système nerveux central .

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Azabenzoxazoles for the treatment of cns disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Azabenzoxazoles for the treatment of cns disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azabenzoxazoles for the treatment of cns disorders will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1378988

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.